WFG Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

WFG Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-737	Closed	-$38K	–	1549
2017 Q1	$38K	Sell	737 -13	-2%	-$601	0.01%	729
2016 Q4	$28K	Hold	750	–	–	0.01%	856
2016 Q3	$51K	Hold	750	–	–	0.01%	699
2016 Q2	$42K	Hold	750	–	–	0.01%	723
2016 Q1	$47K	Hold	750	–	–	0.01%	680
2015 Q4	$71K	Hold	750	–	–	0.02%	555
2015 Q3	$60K	Hold	750	–	–	0.02%	586
2015 Q2	$90K	Hold	750	–	–	0.02%	562
2015 Q1	$78K	Sell	750 -1,295	-63%	-$131K	0.02%	604
2014 Q4	$198K	Buy	2,045 +1,295	+173%	+$120K	0.04%	430
2014 Q3	$59K	Buy	750 +291	+63%	+$18.8K	0.01%	861
2014 Q2	$29K	Buy	459 +409	+818%	+$24.3K	0.01%	1125
2014 Q1	$3K	Hold	50	–	–	﹤0.01%	1715
2013 Q4	$3K	Buy	+50	New	+$2.98K	﹤0.01%	1855

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

WFG Advisors's ALNY Position: Q2 2017 in Review

WFG Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2017, closing a stake of 737 shares — an estimated $38K sold.

WFG Advisors first reported a position in ALNY in Q4 2013 and held it in 14 quarters. The position peaked at $198K in Q4 2014. 227 funds tracked by Wall St. Rank hold ALNY as of Q2 2017.

WFG Advisors reported no remaining Alnylam Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
WFG Advisors sold 737 Alnylam Pharmaceuticals shares in Q2 2017, an estimated $38K.
WFG Advisors first reported a position in Alnylam Pharmaceuticals in Q4 2013 and held it in 14 quarters.
WFG Advisors's Alnylam Pharmaceuticals position peaked at $198K in Q4 2014.
227 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2017.

Based on WFG Advisors's 13F filing for Q2 2017, filed 18 Aug 2017.